These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18193090)

  • 1. PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity.
    Tschan MP; Reddy VA; Ress A; Arvidsson G; Fey MF; Torbett BE
    Oncogene; 2008 May; 27(24):3489-93. PubMed ID: 18193090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73.
    Dietz S; Rother K; Bamberger C; Schmale H; Mössner J; Engeland K
    FEBS Lett; 2002 Aug; 525(1-3):93-9. PubMed ID: 12163168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
    Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
    J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the p53 homolog p73 by adenoviral oncogene E1A.
    Das S; El-Deiry WS; Somasundaram K
    J Biol Chem; 2003 May; 278(20):18313-20. PubMed ID: 12639967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
    Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
    J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN; Sommer K; Sanhaji M; Krämer A; Matthess Y; Kaufmann M; Strebhardt K; Yuan J
    Cell Cycle; 2009 Feb; 8(3):460-72. PubMed ID: 19177004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
    Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
    Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.
    Harr MW; Graves TG; Crawford EL; Warner KA; Reed CA; Willey JC
    Mol Cancer; 2005 Jul; 4():23. PubMed ID: 16014176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.
    Yan W; Zhang J; Zhang Y; Jung YS; Chen X
    Mol Cell Biol; 2012 Jul; 32(13):2336-48. PubMed ID: 22508983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis.
    Holcakova J; Ceskova P; Hrstka R; Muller P; Dubska L; Coates PJ; Palecek E; Vojtesek B
    Cell Mol Biol Lett; 2008; 13(3):404-20. PubMed ID: 18350258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 suppresses p73 function without promoting p73 degradation.
    Zeng X; Chen L; Jost CA; Maya R; Keller D; Wang X; Kaelin WG; Oren M; Chen J; Lu H
    Mol Cell Biol; 1999 May; 19(5):3257-66. PubMed ID: 10207051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of p73 and p53 regulation and effector functions.
    Fang L; Lee SW; Aaronson SA
    J Cell Biol; 1999 Nov; 147(4):823-30. PubMed ID: 10562283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
    Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
    Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter specificity and stability control of the p53-related protein p73.
    Lee CW; La Thangue NB
    Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
    Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
    Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of mitochondrial p53 to dominant inhibition.
    Heyne K; Schmitt K; Mueller D; Armbruester V; Mestres P; Roemer K
    Mol Cancer; 2008 Jun; 7():54. PubMed ID: 18547443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.